- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04544293
Sperimentazione clinica della soluzione per nebulizzatore di Molgramostim per via inalatoria nella proteinosi alveolare polmonare autoimmune (aPAP) (IMPALA-2)
Uno studio clinico randomizzato, in doppio cieco, controllato con placebo sulla soluzione per nebulizzatore di Molgramostim inalato una volta al giorno in soggetti adulti con proteinosi alveolare polmonare autoimmune (aPAP)
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.
An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.
The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
-
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgio, 1070
- Hôpital Erasme
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgio, 3000
- UZ Leuven - Campus Gasthuisberg - Pneumologie
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- University of Calgary
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St Joseph's Healthcare Hamilton Research
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- University Institute of Cardiology and Respirology of Quebec
-
-
-
-
-
Seoul, Corea del Sud, 03080
- Seoul National University Hospital
-
Seoul, Corea del Sud, 05505
- Asan Medical Center
-
Seoul, Corea del Sud, 06351
- Samsung Medical Center
-
Seoul, Corea del Sud, 03722
- Severance Hospital - Yonsei University Health System - Pulmonary
-
-
-
-
Auvergne-Rhône-Alpes
-
Bron, Auvergne-Rhône-Alpes, Francia, 69500
- Hôpital Louis Pradel
-
-
Brittany Region
-
Rennes, Brittany Region, Francia, 35033
- CHU Pontchaillou
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Germania, 69126
- Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
-
-
Bavaria
-
Muenchen-Gauting, Bavaria, Germania, 82131
- Asklepios Fachkliniken Muenchen-Gauting
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Germania, 45239
- Ruhrlandklinik Westdeutsches Lungenzentrum
-
-
-
-
-
Nagakute, Giappone, 480-1195
- Aichi Medical University Hospital
-
-
Chiba
-
Chiba, Chiba, Giappone, 260-8677
- Chiba University Hospital - Respiratory Medicine
-
-
Hokkaidô
-
Sapporo, Hokkaidô, Giappone, 060-8648
- Hokkaido University Hospital
-
-
Kanagawa
-
Yokohama, Kanagawa, Giappone, 236-0051
- Kanagawa Cardiovascular and Respiratory Center
-
-
Kumamoto
-
Kumamoto, Kumamoto, Giappone, 860-8556
- Kumamoto University Hospital
-
-
Miyagi
-
Sendai, Miyagi, Giappone, 980-8574
- Tohoku University Hospital - Respiratory Tract Medicine
-
-
Osaka
-
Sakai, Osaka, Giappone, 591-8555
- National Hospital Organization Kinki-Chuo Chest medical Center
-
-
Saitama
-
Saitama, Saitama, Giappone, 330-8553
- Saitama Red Cross Hospital
-
-
Tokyo
-
Mitaka, Tokyo, Giappone, 181-8611
- Kyorin University Hospital
-
-
-
-
-
Athens, Grecia, 12462
- Attikon University Hospital
-
-
-
-
-
Dublin, Irlanda, DO4 T6F4
- St. Vincent's University Hospital
-
-
-
-
Lombardy
-
Pavia, Lombardy, Italia, 27100
- Fondazione IRCCS Policlinico San Matteo
-
-
-
-
Utrecht
-
Nieuwegein, Utrecht, Olanda, 3435CM
- St Antonius Hospital
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 01-138
- Instytut Gruzlicy i Chorob Pluc
-
-
-
-
Lisbon District
-
Lisbon, Lisbon District, Portogallo, 1769-001
- Hospital Pulido Valente
-
-
Porto District
-
Porto, Porto District, Portogallo, 4200-319
- Hospital São João
-
-
-
-
London
-
London, London, Regno Unito, SW3 6NP
- Royal Brompton and Harefield NHS Foundation Trust
-
-
-
-
Bucharest
-
Bucharest, Bucharest, Romania, 050159
- Institutul de Pneumoftiziologie "Marius Nasta"
-
-
-
-
Catalonia
-
Barcelona, Catalonia, Spagna, 08907
- Hospital Universitario de Bellvitge
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- University Of Arkansas For Medical Services
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- UCLA David Geffen School of Medicine
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80206
- National Jewish Health
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- University of Florida Health
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University
-
-
Illinois
-
Maywood, Illinois, Stati Uniti, 60153
- Loyola University
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland Medical Center
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University in St. Louis
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Stati Uniti, 27610
- Wake Med Health & Hospital
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229-3039
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania Perelman School of Medicine - Pulmonology
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- University of Pittsburgh
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern Medical Center
-
-
-
-
Ankara
-
Ankara, Ankara, Turchia (Türkiye), 6010
- Health Sciences University Gulhane Training and Research Hospital
-
-
Istanbul
-
Istanbul, Istanbul, Turchia (Türkiye), 34020
- Yedikule Chest Disease and Surgery Training and Research Hospital
-
-
İzmir
-
Bornova, İzmir, Turchia (Türkiye), 35100
- Ege University Hospital - Department of Pulmonology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).
-
A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.
-
History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.
-
A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.
-
Change in %DLCO adj of <15% points during the screening period.
-
Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).
-
Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.
-
Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.
-
Male or female
-
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
- Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
-
Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
-
Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.
Exclusion Criteria:
- Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
- Whole lung lavage (WLL) performed within 3 months prior to baseline.
- Requirement for WLL at screening or baseline.
- GM-CSF treatment within 6 months prior to baseline.
- Treatment with rituximab within 6 months prior to baseline.
- Treatment with plasmapheresis within 6 weeks prior to baseline.
- Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
- Previously randomized in this trial.
- History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
- Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
- Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
- History of, or present, myeloproliferative disease or leukemia.
- Apparent pre-existing concurrent pulmonary fibrosis.
- Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
- Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
- Physical disability or other condition that precludes safe and adequate exercise testing.
- Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
- Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
- For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Molgramostim
Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks |
Molgramostim 300 µg nebulizer solution
Altri nomi:
|
|
Comparatore placebo: Placebo
Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks |
Matching placebo nebulizer solution
Altri nomi:
|
|
Sperimentale: Molgramostim Open-label Extension
Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks |
Molgramostim 300 µg nebulizer solution
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
Lasso di tempo: From Baseline to Week 24
|
As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). |
From Baseline to Week 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
Lasso di tempo: From Baseline to Week 48
|
As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange. |
From Baseline to Week 48
|
|
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
Lasso di tempo: From Baseline to Week 24
|
The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health. |
From Baseline to Week 24
|
|
Change From Baseline in SGRQ Activity Component Score to Week 24
Lasso di tempo: From Baseline to Week 24
|
The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity |
From Baseline to Week 24
|
|
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
Lasso di tempo: From Baseline to Week 24
|
As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity. |
From Baseline to Week 24
|
|
Change From Baseline in SGRQ Total Score to Week 48
Lasso di tempo: From Baseline to Week 48
|
The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health. |
From Baseline to Week 48
|
|
Change From Baseline in SGRQ Activity From Baseline to Week 48
Lasso di tempo: From Baseline to Week 48
|
The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity |
From Baseline to Week 48
|
|
Change From Baseline in EC, Expressed as Peak METs to Week 48
Lasso di tempo: From Baseline to Week 48
|
As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity. |
From Baseline to Week 48
|
|
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
Lasso di tempo: From Baseline to Week 24
|
A-aDO2 was used as an additional measure of gas exchange. |
From Baseline to Week 24
|
|
Number of Subjects With Serious and Non-serious Adverse Events
Lasso di tempo: From Baseline until End of Double-blind treatment (Week 48)
|
Assessment of the safety of molgramostim compared to placebo |
From Baseline until End of Double-blind treatment (Week 48)
|
|
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
Lasso di tempo: From Baseline until End of Double-blind treatment Week-48
|
Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline). |
From Baseline until End of Double-blind treatment Week-48
|
|
Changes in Forced Vital Capacity (FVC) %Predicted Normal
Lasso di tempo: From Baseline to Weeks 24 and 48
|
Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity. |
From Baseline to Weeks 24 and 48
|
|
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
Lasso di tempo: From Baseline to Weeks 24 and 48
|
FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function. |
From Baseline to Weeks 24 and 48
|
|
Change in QT Interval Corrected by Fridericia (QTcF)
Lasso di tempo: From Baseline to Weeks 4 and 24
|
Assessment of the safety of MOL compared to placebo |
From Baseline to Weeks 4 and 24
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Bruce Trapnell, MD, Children's Hospital Medical Center, Cincinnati
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Proteinosi Alveolare Polmonare Acquisita
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Fattori biologici
- Carboidrati
- Peptidi e proteine di segnalazione intercellulare
- Glicoproteine
- Glicoconiugati
- Fattori di crescita delle cellule ematopoietiche
- Citochine
- Fattori stimolanti le colonie
- regramostim
- molgramostim
Altri numeri di identificazione dello studio
- SAV006-05
- 2020-001263-85 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .